Heinz Lubenau PhD

Heinz Lubenau co-founded VAXIMM in 2008. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, where he led the development work of the first biosimilar G-CSF Ratiograstim from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2.

In 1994 he joined Servier Forschung und Pharmaentwicklung GmbH as Junior Project leader and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. In this role he was responsible for Servier Phase 1 to Phase 3 clinical trials in Germany, Austria and Switzerland for cardiology, diabetes and hypertension, including the registration trials of Preterax and Procoralan. At this time, he also led clinical project teams and was responsible for hiring clinical project staff. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.